Above all else, we are committed to the care and improvement of human life. In recognition of this commitment, we will strive to deliver high quality, cost-effective healthcare in the communities we serve.
Letter from the Chairman

Maurizio Ghisoli M.D.
Cancer Committee, Chairman

The mission of the Medical City Dallas Cancer Program is to provide the highest quality of oncology healthcare to the North Texas Community. The Oncology Services offered by Medical City Dallas and Medical City Children's Hospital support this mission through a multi-disciplinary team of physicians, researchers, geneticists, nurses, administrators and other healthcare professionals. Together they provide excellent care addressing everything from cancer prevention to diagnostic work-up, from cutting edge treatment to palliative care. While striving to achieve this mission, we are pleased to present to you the 2018 Cancer Program Annual Report recognizing the hard work and many achievements of the Medical City Dallas Cancer Program.

The Medical City Dallas Cancer Programs, both pediatric and adult, are approved by the American College of Surgeons, which assures that the program meets the highest national standards for comprehensive and patient centered cancer care. We are proud to have been awarded three year Accreditation with Commendation through 2018 by the Commission on Cancer (CoC) of the American College of Surgeons—a consortium of 56 professional organizations that reflect the full spectrum of cancer care. To earn accreditation, Medical City Dallas Cancer program successfully completed an on-site CoC evaluation to verify compliance with all established CoC Standards.

I would like to provide you with a brief overview of our comprehensive services and present statistics regarding cancer patients diagnosed and treated at our facility in 2018. At Medical City Dallas we provide cancer care in the fields of Oncology/ Hematology (adult and pediatric), Radiation Oncology, Bone Marrow Transplantation, Oncologic Gynecology and Urology, Oncologic Surgery, Thoracic Surgery and Palliative Care. The Medical City Dallas Cancer registry data for 2017 included approximately 2,800 new cancer patients. With the inclusion of non-analytical cases, the five most prevalent sites treated were breast (223), leukemia (133), lung (113), uterine corpus (92) and non-Hodgkin lymphoma (94), demonstrating some difference from national incidence. Our Stem Cell Transplant Program has become one of the strongest in the area, with 221 transplants in 2018 an outstanding FACT accreditation .2019 promises to be a continuation of excellence in cancer care as we look forward to significant expansion in of services and facilities.

At Medical City Dallas Cancer Program, we provide dynamic educational conferences, including tumor boards with patient centered prospective discussion of diagnosis and treatment options by a team of multidisciplinary physicians. In accordance with AJCC standards, all cases presented include clinical and pathological staging, followed by discussion of treatment plan. We also have multiple educational conferences providing physician and ancillary staff education. Over 200 patients have been prospectively discussed in 2018, along with many other conferences including: Genetics and Genomics.

The Medical City Dallas Cancer Program is committed to a patient centered approach; as evidenced by the multitude of outreach and cancer prevention activities coordinated by Medical City Dallas Cancer Staff and provided to our patients and families. Just to mention few of them: MAKERplay Program, Heroes for Children 5K, Wheel to Survive, Light the Night Walk, and Camp iHope. We also provide one of the strongest Navigation Programs that is integrated with the Sarah Cannon and HCA global oncology service line. Our Medical City Dallas Cancer Resource Center, in
2018, had more than 2,100 visitors. Our pediatric social work and child life team also works hand in hand with the Make a Wish foundation to assure that each child sees his or her dream come true.

Our Cancer Program recognizes the complex needs of survivors, as well as patients who require ongoing cancer treatment. It is an honor and privilege to serve as Chairman of the Cancer Committee. We pledge our commitment to provide the highest level of cancer care which our North Texas community deserves. We try to never forget that each person treated at our facility deserves personalized, patient centered attention. I cordially invite you to review our Annual Report.
Breast Center at Medical City Dallas

Under the talented and insightful leadership of Dr. Alison Laidley, the Breast Center at Medical City Dallas is fully accredited by the National Accreditation Program for Breast Centers (NAPBC). The breast program was awarded its initial accreditation in 2012 and recertified in 2014 and 2017. Accreditation by NAPBC recognizes those centers that have voluntarily committed to providing the highest level of quality breast care. The breast program agreed to undergo a rigorous evaluation process and review of their performance.

The Breast Center at Medical City Dallas offers the comprehensive services patients need for breast health including breast cancer screening, diagnosis, education, and treatment in one coordinated program. Focusing exclusively on breast health, our team includes dedicated breast imagers, breast surgeons, plastic surgeons, medical oncologists, radiation oncologists, pathologists, and experienced oncology nurses. Our breast care professionals work collaboratively with extensive support services such as cancer genetic counselors, breast care navigators, social workers, dieticians, pharmacists, physical therapists, lymphedema specialists and mental health counselors.

The Breast Center at Medical City Dallas prides itself in providing comprehensive, personalized, high quality breast care including state-of-the-art risk assessment, testing, diagnostic and treatment options. In addition to 3-D tomo-synthesis, the Breast Center offers Magnetic Resonance Imaging (MRI) and ultrasound. The Center also offers innovative biopsy techniques, including less invasive stereotactic and image-guided procedures. The Breast Center at Medical City Dallas has a dedicated mammography radiologist and offers convenient scheduling. Medical City’s breast surgeons and plastic surgeons specialize in breast cancer surgery and in advanced breast reconstruction techniques, such as DIEP procedure.

For more information about the National Accreditation Program for Breast Centers, visit their Web site at: www.accreditedbreastcenters.org
Founded in 1994, the Medical City Dallas Blood and Marrow Transplant Program has remained accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) and also by the National Marrow Donor program (NMDP). Additionally, our Cellular Therapy Laboratory, where the stem cells are processed and stored, is FDA registered and led by Dr. Joel Weinthal, the Medical Director of the Cellular Therapy Lab and Apheresis. Within the span of 2 decades, the program has expanded quite a bit. The program, under the guidance of Medical Director, Dr. Vikas Bhushan, is rare in that every type of transplant is performed at Medical City Dallas, including both adult and pediatric autologous, allogeneic, related, unrelated, umbilical cord and haploidentical. It is the haploidentical transplant that has garnered interest over recent years, 22 of which were performed in 2018.

In October, the program performed a staggering 28 transplants and will finish the year with 221 transplants in total. Due to the strong, sustained growth this program has seen, providing sustainable infrastructure was amongst some of the program’s top goals for 2018 and will continue to be so in 2019. Overall, the program saw a healthy 16% increase YOY and is poised for incremental growth in 2019. The full-time arrival of Dr. Estil Vance and the initiation of CAR-T therapy were some of the program’s greatest additions this year. CAR-T, also known as chimeric antigen receptor T-cell therapy, is a type of treatment where the patient’s T cells (a type of immune system cell) are harvested and genetically manipulated in a laboratory to target and attack the cancer cells. This exciting new treatment offers the latest engineering of patient’s immune cells to treat their cancers. The 1st patient at MCDH to undergo this treatment was seen in December of this year. The program is poised to offer this cancer treatment to both the adult and pediatric patient population, ages 18 and older. This new therapy will strengthen the patient’s immune system to fight their existing cancer.
Scope of Services

- Autologous Transplants (Adult and Pediatric)
- Allogeneic Transplants (Adult and Pediatric)
  - Related
  - Unrelated
  - Umbilical Cord
  - Haploidentical
- Hospital has 20 Inpatient Transplant dedicated rooms in Bldg A-11S with hepa-filters and positive pressure with additional 18 beds on our step-down unit, 12S
- Texas Oncology Outpatient Transplant Clinic
- HPC Collection Facility (Marrow and Apheresis)
- HPC Processing Facility
- Oncology Rehab
- Patient Education Class
- Caregiver Support Group
- Full Member of Children's Oncology Group and a COG-designated Autologous/Allogeneic Transplant Center
- Clinical Centers of Excellence
  - AETNA Institutes of Excellence
  - Blue Cross Blue Shield Blue Distinction Centers
  - CIGNA LifeSOURCE Transplant Network
  - OPTUM
  - Humana National Transplant Network

2018 CIBMTR Survival Outcomes

<table>
<thead>
<tr>
<th>Center Name</th>
<th>n</th>
<th>Actual (%)</th>
<th>Predicted (%)</th>
<th>Lower (%)</th>
<th>Upper (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical City Dallas Hospital*</td>
<td>155</td>
<td>75.5</td>
<td>70.5</td>
<td>63.7</td>
<td>77.4</td>
</tr>
<tr>
<td>Children’s Medical Center– Dallas</td>
<td>77</td>
<td>76.6</td>
<td>80.5</td>
<td>71.9</td>
<td>88.7</td>
</tr>
<tr>
<td>UT Southwestern Medical Center</td>
<td>79</td>
<td>68.4</td>
<td>73.7</td>
<td>64.5</td>
<td>82.7</td>
</tr>
<tr>
<td>Cook Children’s Medical Center</td>
<td>59</td>
<td>77.6</td>
<td>83.5</td>
<td>74.7</td>
<td>92.0</td>
</tr>
<tr>
<td>Baylor</td>
<td>325</td>
<td>58.6</td>
<td>64.7</td>
<td>60.0</td>
<td>69.7</td>
</tr>
</tbody>
</table>

*The only BMT program in the DFW market that exceeded their predicted survival outcomes.
One of the infrastructure needs growing programs have is operational and patient space. The hospital has undergone several changes over the last 12 months to accommodate more blood cancer patients than ever before. With the opening of a brand new Apheresis and Infusion Center as well as a new Cellular Therapy Lab on 4 South in February, the program has ample room to increase transplant load and aftercare. The BMT unit expanded to 40 beds in January 2018, and the Blood Cancer unit expanded to 43 beds in July.

A participant of the Sarah Cannon Blood Cancer Network, our team members have frequent interaction with blood cancers and stem cell transplant professionals across 6 different programs nationwide. The experience of this network is reflected in the more than 11,000 transplants performed since the inception of the very first program. By joining this network, we have made a commitment to work with these other programs in the Network to standardize our quality, infrastructure, training and our future research to provide an unparalleled and world-class experience for our patients seeking treatment for blood cancer.

Sarah Cannon has built significant capabilities across its BMT centers, in the US and UK, performing over 11,000 transplants.
At Medical City Dallas, our adult oncology patients are cared for by a dedicated team of oncology nurses who have completed the Oncology Nursing Society Chemotherapy and Biotherapy course and receive extensive training in Oncology. We were the first to be recognized as a Magnet hospital in Dallas for excellence in nursing care by the American Nurses Credentialing Center (ANCC), and we continue to be accredited.

There are five dedicated inpatient Oncology units and one dedicated outpatient unit in our facility. The inpatient units include Medical/Surgical Oncology, two Hematology Oncology units, Stem Cell Transplant and a Gyn-Oncology unit. In addition, we have an outpatient unit where our apheresis and infusion patients are treated. Our general pediatric oncology population is cared for by dedicated staff in the Medical City Children’s hospital.

Our Director; Rodney Moffett, BSN, RN, BMTCN has been in Oncology Nursing for over 30 years, with an extensive background in leadership. He is dedicated to clinical excellence and patient experience. He oversees our inpatient nursing departments and supports all aspects of our program including the Cancer Resource Center, outreach, navigation, registry, and the Cancer Genetics program. His vision for oncology continues to be providing a comprehensive approach to cancer care focusing on quality outcomes while providing compassionate care to our patients. Rodney is passionate about advancing and supporting oncology nursing through collaborative relationships and specialty certification.

The Hematology Oncology Units are overseen by Mary Elizabeth Barnhouse BSN, RN, OCN. Beth is dedicated to leading her nursing teams to Oncology Excellence. She has 25 years of Stem Cell Transplant and Oncology experience. This department has rapidly expanded this year to 43 beds. The Hematology staff has 5% of eligible nurses certified in Oncology Nursing by the Oncology Nursing Society.
The Medical/Surgical Oncology Unit is led by Kristen Anderson BSN, RN, CNRN. Kristen is very passionate about developing the team to clinical excellence. She has been an RN for eight years, in progressive leadership roles. The Medical/Surgical staff has 16% of eligible nurses certified in Oncology Nursing by the Oncology Nursing Society.

Kristen also oversees the Apheresis and Infusion outpatient department, which is staffed by registered nurses cross-trained to work in both apheresis and infusion procedures. The outpatient infusion department services include administration of chemotherapy, electrolyte replacement therapy, and antibiotic infusions. Apheresis services include stem cell collection for patients that are receiving transplants and therapeutic treatments for graft versus host disease and a wide variety of diagnosed conditions.

The Stem Cell Transplant Unit is led by Victoria Tierney, BSN, RN, BMTCN. Victoria has 10 years of nursing experience in the treatment and care of Oncology and Blood and Marrow Transplant patients. The Stem Cell Transplant Unit at Medical City performs autologous, allogeneic and cord blood transplants. Pediatric transplants are performed in our Stem Cell Transplant Unit by trained pediatric transplant nurses. Currently, 84.6% of eligible nurses are certified in Oncology or Bone Marrow Transplant through the Oncology Nursing Society.

Another highly specialized group of Oncology professionals that is dedicated to providing exceptional care and achieving quality outcomes for our Oncology patients through nursing development and education is our nursing support team. The team includes Molly Prescott, BSN RN BMTCN, Program Manager, Sashi Jyothik, MSN RN OCN, Oncology Nurse Educator, and Michelle Baker BSN RN OCN, our Hematology and Oncology Care Coordinator.
Medical City Dallas Hospital Cancer Registry is an integral component of the cancer program. The registry performs data collection and lifetime follow-up on all cases diagnosed and treated at the Medical City Dallas Hospital. Data is collected according to current American College of Surgeons Commission on Cancer (CoC) as well as the Texas Department of State Health Services (DSHS), Texas Cancer Registry (TCR) data standards and coding instructions. The data is vital for both programmatic and administrative planning, as well as for research and to monitor patient outcomes. Some of the data collected include patient characteristics, site, histology, American Joint Committee on Cancer (AJCC) staging, first course of treatment, disease recurrence (if applicable) and survival information. Registry data is an effective resource that dictates and drives how the cancer program establishes goals and measures accomplishments.

In 2017, the registry accessioned 2,847 cases for Medical City Dallas, of which 1,510 were analytical cases, while 1,337 were non-analytical; 1,273 were men and 1,574 were women. There are approximately 12,603 patients currently alive and under active annual follow-up. In addition to providing critical information about disease status and treatment outcome, the follow-up process also performs a valuable service for physicians and patients by reminding patients that regular reassessment of their disease is vital for early detection of local recurrences, possible metastases or development of subsequent primaries.

The data presented in this annual report summarize Medical City Dallas experience for 2017. As in previous years, breast cancer continues to be the most prevalent disease, with 223 cases accessioned. Leukemia is the second most frequent disease, with 133 cases. Lung, Lymphoma and Corpus uterus complete the top five sites, with 113, 94 and 92 cases, respectively. The top 5 sites comprise 43% of all newly diagnosed cases. The Cancer Registry goal is to provide accurate and timely data to healthcare providers and administration for use in studies, research, and planning.
National Leading Sites of New Cancer Cases - 2017 Estimates by Gender

*Source: The American Cancer Society Cancer Facts & Figures 2017

Medical City Dallas Hospital - 2017 Top 5 Sites

†■ Corpus Uterus
‡■ Lymphoma
⌂△ Lung
►▲ Leukemia
◄▲ Breast
Raising Awareness during Lung Cancer Awareness Month—"Great American Smoke Out"

Lung Cancer Navigator—Cathy Simmons, BSN, RN
Clinical Accruals for 2018

The adult and pediatric cancer programs are dedicated to improving the lives of the patients and families we serve. The dedicated team of professionals knows that cancer research has been the driving force in higher survival rates and improved quality of care for both children and adults with cancer. At diagnosis patients and their families are provided with up to date information and treatment options for their specific type of cancer. In addition, they are afforded the opportunity to participate in any open clinical trials for their disease. Because of the active clinical research program at Medical City and Medical City Children’s Hospital our patients receive state of the art treatment. By doing this, we make a difference in the future care of cancer.

2018

<table>
<thead>
<tr>
<th>Trial Type</th>
<th>Onsite</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio Repository Trials/Patient Registry Trials</td>
<td>Onsite</td>
<td>29</td>
</tr>
<tr>
<td>Screening</td>
<td>Onsite</td>
<td>2</td>
</tr>
<tr>
<td>Quality of Life Trials</td>
<td>Onsite</td>
<td></td>
</tr>
<tr>
<td>Treatment Trials</td>
<td>Onsite</td>
<td>11</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>42</td>
</tr>
<tr>
<td>Annual Analytic Caseload</td>
<td></td>
<td>1502^</td>
</tr>
<tr>
<td>Percent Accrued</td>
<td></td>
<td>2.7%</td>
</tr>
</tbody>
</table>

*Reported data is for COG studies only. ^projected analytic caseload based on 2017 totals.
The Medical City Dallas Palliative Care (PC) Program officially began seeing patients on April 25, 2011. The program has experienced consistent growth throughout the past 7 years with exceptional stakeholder support from physicians and staff. The PC team works closely with the patient’s attending physician. The team includes a Medical Director and a Nurse Practitioner who is Certified Hospice / Palliative Nurse (CHPN) with support from Chaplaincy, Rehab, Dietary and Case Management Services. The primary goal of palliative care is to enhance a patient’s quality of life throughout a debilitating illness, whether curative or non-curative in nature.

The following table outlines service provision for the year 2017/2018:
One of the most exciting highlights from 2018 came when construction was started on our new state of the art pediatric oncology unit. Input from all stakeholders was incorporated into the planning. It was important to the team that the unit provide the highest standards in infection prevention, but also that the needs of patients and families who may spend several days to months in the hospital be met through the design. An environment has been created that is dedicated to providing the best medical treatment available, but just as importantly, a space that supports healing for children and their families. The rooms are built with long term patients in mind. There are areas to display personal items, work, and different lighting to accommodate both the patient and family. A Playroom, Teen Room, Family Room, and Conversation area are included in the unit to provide an opportunity for patients and families to be active, and provide support to one another. This 12-bed, completely hepafiltered unit is scheduled to open the first quarter of 2019.

Team members were very involved with ensuring high quality care, not only for the children and families we serve... but also those within our community and beyond:

- Dr. Ghisoli’s Phase I vaccine trial for metastatic Ewing’s Sarcoma patients has had such good results that it has reopened as a Phase II Trial. The Vigil Trial is now open at 7 centers around the country.

- Dr. Lampson opened the Celebration Clinic this year. This clinic serves oncology patients who are 2 or more years off therapy. Recognizing that health concerns for childhood cancer patients does not end when cancer is successfully treated, the Celebration Clinic provides care and education to ensure our patients learn how to maintain and maximize good health.
• Drs. Lenarsky, Ghisoli, and Weinthal continued their service as adjunct clinical faculty for the Department of Pediatrics, Texas College of Osteopathic Medicine for the University of North Texas Health Science Center of Fort Worth. Through this program they are participating in educating the next generation of physicians.
• Claudia Sebastian, RN and Jennifer Brannum, RN served in leadership positions for the DFW Association of Pediatric Hematology/Oncology Nurses (APHON).
  Angela Beck, RN continued to provide the hematology/oncology nursing lecture to students at Collin County College.

Members of the Pediatric Oncology Team were key in several oncology initiatives this year:

• Successful ACOS and FACT accreditation surveys.
• CAR T Therapy Program

Our Pediatric Oncology team participated in many community and supportive care initiatives for our families. Here are a few highlighted events from 2018:

• Wipe Out Kids Cancer Ambassador Program
• Carson’s Crusaders
• Rutledge Cancer Foundation
• Wildflower Festival Event
• 1 Million for Anna
• Baskets of Hope—providing resources and support to newly diagnosed cancer families
• Heroes for Children 5K
• Annual Adam’s Animals event
• YTRAC 5K—thanks to Young Texan’s Against Cancer (YTAC) who provide the majority of Camp iHope’s funding each year
• Annual Holiday Party for patients and families
• MAKERplay
• Sunshine Kids California Adventure Trip

Sunshine Kids Trip

• Lollipop Theatre showing of “The Grinch”
• Annual Cowboy’s Holiday Visit
• Camp iHope

Camp iHope is a very special camp for children with cancer and their siblings 7-16 years of age. This camp is funded through the Camp iHope Foundation and serves children treated at Medical City Children’s Hospital and any child in the North Texas area without a camp home. Camp iHope is all about a normal childhood experience and having fun! Camp builds confidence, self-esteem, and provides a network of support. It is through this experience that very specific outcomes are achieved that help our campers deal with a cancer diagnosis.
This summer 122 children were able to experience the magic that is Camp iHope.

Disney was chosen for this summer’s theme as we chose to “Believe” in magic, hope, and joy!

Here are a few pictures of their experiences...

Winners of the Lip Sync Battle
Our community is **Key** to the success of Camp iHope…

Camp would not be possible without the generous financial and in-kind support we receive from the North Texas Community. It costs approximately $1000 to send a child to camp. YTAC (Young Texans Against Cancer) holds an annual 5/10K each spring to raise money for Camp iHope. They are our single largest donor. This past year they raised $40,000 for camp. In addition we receive grant funding, individual donations, and in-kind support to cover the costs of camp.

Our Volunteers…

We had 64 full-time staff for the week between program staff, counselors, and medical staff. They come from all walks of life…healthcare, teachers, business; we had 18 childhood cancer survivors on our staff this year. In addition, we had an additional forty volunteers give their time to help with special daytime or evening activities. Many of our day volunteers were from groups that have also helped financially sponsor Camp iHope such as YTAC, BCBSTX, Cake Club of North Texas, and MCCH Child Life Department.
Over the past few years, Oncology Navigation has become a high priority initiative within HCA facilities, and in 2013 Sarah Cannon (SC) introduced a systematic, fully integrated Nurse Navigation program within the Medical City Healthcare Division. As HCA’s global oncology service line, Sarah Cannon is partnering with the division markets to develop and ensure delivery of best-in-class oncology care for our patients, physicians, and payers.

Sarah Cannon’s expertise and resources are shared and expanded upon in structured interdisciplinary site specific workgroups. These groups meet periodically and are responsible for programmatic development, workflow implementation, and monitoring across the division. The workgroup’s goal is to create a continuum of care of the highest quality, with consistency across the market’s hospitals and outpatient facilities.

Sarah Cannon has created a patient navigation system that addresses the entire continuum of cancer care. The system is designed to support nurse navigators in all phases of the treatment spectrum, including prevention, screening and early detection, diagnosis, treatment, and palliative care. By tracking progress, facilitating communication, and producing reminders, the I-Navigate documentation system is a vital tool in the expansion of Sarah Cannon’s capabilities to support metric adherence and outcome goals.

The Sarah Cannon Navigation program at Medical City Dallas has grown since its inception to include seven cancer site-specific nurse navigators. Our navigators include a Breast Cancer Navigator, Complex GI Navigator, Gynecologic/Oncology Cancer Navigator, Lung Cancer Navigator, Neuro/ Sarcoma Navigator and two Survivorship Navigators. The program currently serves approximately 70 oncology patients a month, for a total of 830 patients in 2017 and 787 patients in 2018 to date.
Roles and Responsibilities of Sarah Cannon Oncology Nurse Navigators at Medical City Dallas:

- Function as members of the multidisciplinary team who advocate and educate for patients from point of entry, through diagnostic studies, diagnosis and treatment plan for cancer through survivorship.

- Build relationships with patients and physicians, to coordinate a plan of care including appointments, transportation, education, provision of and/or access to support services, and representation within the multidisciplinary care environment.

- Serve as a liaison between the patient and family, primary care physician, specialists, internal and external care providers, referral services, and support resources within the hospital setting as well as the community setting.

Community Health Needs Assessment and Oncology Nurse Navigation Program

In an effort to better serve the needs of the community that Medical City Dallas serves, the Sarah Cannon model of patient navigation strives to eliminate barriers to quality care and ensure speedy, optimal delivery of appropriate services.

Oncology Nurse Navigators assist with:

- Meeting the patient wherever they are along the cancer care continuum to identify healthcare disparities and barriers to care.

- Increasing patient and family education and awareness about cancer and support services.

- Encouraging self-efficacy with patients in communication, resources, advocacy, and education.

- Planning and implementation of cancer-related community outreach events.
This year HCA Healthcare celebrated a landmark year, the 50th anniversary of its founding by Dr Thomas Frist Sr., Dr Thomas Frist Jr., and businessman Jack Massey. Since the company’s formation in 1968, HCA has grown from a single hospital in Nashville, TN, to an extensive system of healthcare facilities with a shared mission “to provide the best possible care to patients and to do so with warmth and compassion.” It was Dr Frist, Sr. who uttered the words, “Good people beget good people.”

Every day on our cancer floors I witness “good people doing” simple but amazing ACTS of warmth and compassion. We can never fully fathom all that goes on each day, but I am reminded that we are all part of a team. Let us take encouragement from Mother Teresa who said: “You can do what I cannot do; I can do what you cannot do. Together we can do great things.” Often, we cannot measure the things that we do, but please take heart in the knowledge that what you do daily is so important in the help and healing of others. When we work together as a team there is a synergy that takes place. What is synergy: The interaction or cooperation of two or more persons or floors to produce a combined effect greater than the sum of their separate effects.

Thanks for allowing the other chaplains and me to be a part of your team. As you all know we experience many blessings and face many challenges as a team. It is wonderful to see many patients leave our hospital healed after a series of complex treatments. On the other hand, we also have a chance to remember those who are not so fortunate. Thank you for allowing me to debrief with you during those several times of remembrance. I know we were all touched recently by the song of former patient, Jim Lipscomb, “Somebody’s Praying.”

Hair donations on Medical City Goes Pink go to the Pink Hearts Fund to make wigs for children. Many thanks to our professional volunteer hair cutters!
In 2017/2018, the Clinical Cancer Genetics Program at Medical City Dallas continued to expand both clinical and outreach services. Our patient volume increased by 1.2% from 2016 to 2017, and in 2018, volume is expected to have increased by about 28%. We saw 30 or more patients each month in clinic, with the exception of February 2018 when only 22 patients came in for an appointment. Though our clinic experienced higher than expected no-show and cancellation rates for the months of September and October 2018, the clinic still had a record number of patient appointments attended for those months compared to previous years. Of note, the clinic set a new record of number of patients seen in one month in November 2018 by seeing 40 patients total, despite our full-time genetic counselor’s absence from clinic for two weeks for a professional conference and Thanksgiving holiday. In 2018, our clinic broke our record for highest number of patients seen per month several times throughout the year, and our volumes continue to grow.

At the program’s inception in late 2008, the clinic consisted of only one part-time genetic counselor. Since then, the program has grown to our current staff of two counselors, one full-time and one part-time, and one full-time genetic counseling assistant. We will be bringing on a new PRN genetic counseling assistant to assist with the growing patient volume and workload in January 2019. We also have a current student intern who is able to observe appointments and help with clinic projects.
With more than 275 physicians referring in both our hospital system and the community at large, our patients come to us from all over the DFW Metroplex and beyond. In the last two years, genetic testing was done and counseling was provided for families with a variety of cancer predisposition syndromes including Hereditary Breast/Ovarian Cancer (HBOC), Lynch (Hereditary Non-Polyposis Colorectal Cancer), Multiple Endocrine Neoplasia Type 1 (MEN1), Multiple Endocrine Neoplasia Type 2 (MEN2), Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC), Neurofibromatosis type 1 (NF1), von Hippel-Lindau (VHL), DICER1 syndrome, and Hereditary Paraganglioma/Pheochromocytoma (PGL/PCC). We also counseled families with other hereditary cancer gene mutations including ATM, CHEK2, PALB2, BARD1, BRIP1, MITF, HOXB13, NBN, and more. In most cases, detection of a deleterious mutation significantly changed patient management. For families testing positive for a deleterious mutation, the program provides education regarding current NCCN® guidelines for screening and medical management. Based on these guidelines, a number of individuals counseled through our program underwent prophylactic surgeries and/or increased screening to reduce and manage cancer risk. Through the genetic counseling process, we also help patients and families adjust to the presence and knowledge of an inherited cancer gene mutation, and provide relevant resources and support for them and their families specific to hereditary cancer.

With regard to psychosocial support, our cancer genetics team also participates in coordination and execution of an all-day educational seminar aimed specifically at providing information and support to cancer gene mutation positive families. At our 12th annual DFW Hereditary Patient Conference on September 29th, 2018, we had 60 participants and approximately 25 cancer professionals in attendance. This annual conference was held at Texas Presbyterian Hospital. The response to these conferences has been overwhelmingly positive, with families reporting that they are “extremely helpful”.


Courtney Bell, BS and Stacy M. Utay, MS CGC
The program also continues to provide genetics education to a variety of patients and medical professionals through tumor board presentations and talks to support groups, physician offices, professional meetings, and community groups, and through development of educational materials. In April, we staffed a table alongside nurse navigation at the Texas Credit Union Health Fair from 8:00 am to 1:00 pm to educate their staff about hereditary cancer, cancer risks, and cancer prevention. In May, Stacy spoke at Medical City Plano’s Cancer Survivorship Dinner on the 9th and Sheryl staffed a Cancer Genetics table at the Medical City Plano Cancer Prevention Fair from 7:30 am to 12:00 pm on the 12th. Medical City Dallas also hosted the DFW Cancer Genetics quarterly meeting on the 14th and discussed direct-to-consumer testing and the impact on patients and genetic counselors. In June, Sheryl presented to the Us Too Support Group for prostate cancer.

In July, Sheryl presented at the Medical City Dallas Wednesday conference on hereditary cancer updates and direct-to-consumer testing. At the end of July, our clinic staffed a Cancer Genetics table at the In The Know Cancer Series at Faith Presbyterian Hospice from 8:00 am to 11:30 am. In October, Stacy coordinated a breast cancer awareness and education program with a panel of speakers at Temple Emanu-El; she also served on the panel to discuss the value of genetic counseling and testing, particularly in the Ashkenazi Jewish population due to the high carrier frequency of BRCA mutations (1 in 40 individuals). Sheryl presented in October at Faith Presbyterian Hospice at their In The Know Cancer Series to health professionals and gave an overview of hereditary cancer syndromes and who should consider genetic testing. Also in October, Cancer Genetics staffed a table at the Medical City Goes Pink breast cancer awareness event.

We serve as a resource for all 14 hospitals in the Medical City Healthcare system and for any area physicians and provide high quality genetics care and support to patients. We look forward to continued growth and more opportunities to educate healthcare providers and the community alike in 2019.
Oncology Support Services;

Oncology Support Services; Community Resources, Prevention & Screening.

It is the goal of the Medical City Dallas Cancer Program to provide our patients with the highest quality of oncology care and support patients as they face life-changing, challenging diagnoses. Cancer care has become increasingly complex and personalized, and it is essential to use an inter-disciplinary approach involving a collaborative team of oncology healthcare providers to address not only the patient’s physical issues, but also their psychosocial, informational and care coordination needs as well.

Medical City Dallas Cancer Resource Center

Being diagnosed with cancer can be an overwhelming and confusing time for patients. Medical City Cancer Resource Center is a tranquil, inviting oasis that is dedicated to providing essential information, emotional support, education and referrals to hospital and community resources. The Cancer Resource Center had more than 2,100 visitors in 2018. Medical City Dallas Cancer participated in community outreach events, reaching over 750 people. This includes US TOO Prostate Cancer Support Group and Healthy Connections for gynecologic cancers. This year’s cancer screening event focused on skin cancer. Skin cancer is one of the top 5 cancers treated at our facility. The event was well attended and resulted in a few referrals by our volunteer specialist for follow up.

Our annual awareness, education and prevention events included the “Great American Smoke Out” and “Shine a Light” events for Lung Cancer Awareness and “Medical City Dallas Goes Pink”; our Hospital-wide breast health Prevention and education event and several outreach efforts by our genetics team. They represented Medical City Dallas at the “In the Know” Cancer Series and led out on a discussion panel at Temple Emanu-El’s cancer prevention event.

As corporate participants for the “Light the Night” Walk with the Leukemia and Lymphoma Society we raised over $6,000. Medical City also sponsored the “Wheel to Survive” bike riding event by the Be the Difference Foundation that raises awareness of ovarian cancer. The resource center also partners with the American Cancer Society (ACS) to provide community-based programs like Look Good Feel Better, which is designed for women dealing with hair loss and skin changes due to the effects of treatment.
Medical City Healthcare Team at Wheel to Survive 2018

Medical City Goes Pink—we love it when employees give back!
Patients and their family members have found the resource center to be a place where they can get information about various cancers, referrals to community programs as well as a place to obtain numerous comfort items like wigs, pillows, turbans/hats and blankets to help them navigate after a cancer diagnosis. The following table highlights item totals shared in 2018.
Community volunteers are another essential part of our program and provide dedicated services off-campus to support our hospital’s oncology patients throughout the year. All donations are coordinated through the Guest & Volunteer Services department at Medical City Dallas Hospital & Medical City Children’s Hospital. Other community volunteers that offer a variety of valuable services to oncology are Jerrilyn Oaks, Adam’s Animals, On Pins and Needles, Thoughtful Threads, Passing the Hat & Passing the Hat - KIDS CLUB, Project Linus – Collin/Dallas/Denton/Grayson/Rockwall Counties, Texas Chapter and Sew Blessed Pillows.

Chase Bryant (American singer-songwriter) visits with one of our oncology patients.

Camp iHope 2018 “Believe” in Magic, Hope & Joy
Cancer Committee Members 2018

Dr. Maurizio Ghisoli   Rodney Moffett, RN   Deborah Echtencamp, RN   Katie McCamey, RN
Dr. Mitchell Magee   Beth Barnhouse, RN   Michael Epshtein, PharmD   Molly Sutton, RN
Dr. Ronald Kerr   Caroline Belote, SW   Angela Brown, PT   Jay Devenny
Dr. John O’Connor   Kimberly Cook   Hilary Payne   Maria Custodio
Dr. Lindsay Waters   Sheryl Walker, MS CGC   Janet Reynolds   Renee Akers
Dr. Lincoln Patel   Dr. Michael Limerick, PhD   Janet Reynolds   Robin McCune, RN
Dr. Phil Huber   Stephanie Craddock   Brian Quinn, Chaplain   Penny Perry, CR
Dr. Bradford Hirsh   Charles Swanson, RN   Siobhan Cole, ACS   Serena Perez
Dr. John Matthews   Carla Stewart, MBA   Emily Gentry, RN   Stacy Utay, MS CGC
Sue Johnson, RN   Melissa Threlkeld

Medical City Dallas Goes Pink - Breast Cancer Awareness 2018
Alison Laidley, M.D., FACS (Center, holding ribbon)